SCYNEXIS, Inc.'s Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments  
11/12/2012 9:31:23 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SCYNEXIS, Inc. announced today the results of a Phase 2a study of lead candidate SCY-635 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) for the treatment of the hepatitis C virus (HCV) that showed SCY-635 has the potential to play an important role in the reversal of immune exhaustion, restoring the immune systems of difficult to treat patients with HCV. The presentation “Short Duration Treatment with SCY-635 Restores Sensitivity to Peg-IFN/RBV in Difficult to Treat, IL28B TT/CT, HCV Genotype 1 Patients” was given by lead investigator Dr. Andrew J. Muir at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts. The results demonstrate that SCY-635 has the potential to open up a new frontier in immunotherapy for the treatment of HCV as a synergistic Direct Acting Antiviral (DAA) and a stimulator of the host immune system (Immune Acting Antiviral or IAA), augmenting existing treatments.